BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33840347)

  • 1. Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies.
    Wang JJ; Zhang N; Richardson SA; Wu JV
    Expert Rev Mol Diagn; 2021 Apr; 21(4):363-370. PubMed ID: 33840347
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
    Gillot C; Favresse J; Maloteau V; Dogné JM; Douxfils J
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.
    Yin Q; Zhang Y; Lian L; Qu Y; Wu W; Chen Z; Pei R; Chen T; Sun L; Li C; Li A; Li J; Li D; Wang S; Guan W; Liang M
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.
    Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test.
    Zhang Y; Chen Y; He Y; Li Y; Zhang X; Liang J; He J; Lu S; Gao Z; Xu J; Tang Y
    Talanta; 2023 Apr; 255():124200. PubMed ID: 36565525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods.
    Banga Ndzouboukou JL; Zhang YD; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1052-1064. PubMed ID: 34935114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Pieri M; Nicolai E; Nuccetelli M; Sarubbi S; Tomassetti F; Pelagalli M; Minieri M; Terrinoni A; Bernardini S
    Arch Virol; 2022 May; 167(5):1285-1291. PubMed ID: 35377034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Ferrer J; Forqué L; Costa R; de la Asunción CS; Huntley D; Gozalbo-Rovira R; Buesa J; Giménez E; Rodríguez-Díaz J; Geller R; Navarro D
    J Med Virol; 2021 Apr; 93(4):2301-2306. PubMed ID: 33236799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum.
    Abidi SH; Imtiaz K; Kanji A; Qaiser S; Khan E; Iqbal K; Veldhoen M; Ghias K; Simas JP; Hasan Z
    PLoS One; 2021; 16(12):e0259551. PubMed ID: 34890401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test.
    Chan MMH; Leung KY; Zhang RRQ; Liu D; Fan Y; Khong MKW; Tam AR; Chen H; Yuen KY; Hung IFN; Chan KH
    Microbiol Spectr; 2022 Apr; 10(2):e0099321. PubMed ID: 35254121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.
    Fulford TS; Van H; Gherardin NA; Zheng S; Ciula M; Drummer HE; Redmond S; Tan HX; Boo I; Center RJ; Li F; Grimley SL; Wines BD; Nguyen THO; Mordant FL; Ellenberg P; Rowntree LC; Kedzierski L; Cheng AC; Doolan DL; Matthews G; Bond K; Hogarth PM; McQuilten Z; Subbarao K; Kedzierska K; Juno JA; Wheatley AK; Kent SJ; Williamson DA; Purcell DFJ; Anderson DA; Godfrey DI
    EBioMedicine; 2021 Dec; 74():103729. PubMed ID: 34871960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and multi-center clinical trials of an up-converting phosphor technology-based point-of-care (UPT-POCT) assay for rapid COVID-19 diagnosis and prediction of protective effects.
    Zhang P; Li B; Wang Y; Min W; Wang X; Zhou Y; Li Z; Zhao Y; Zhang H; Jiang M; Zheng H; Yang C; Zhang W; Zuo L; Gao Q; Yang Z; Li Y; Feng T; Lin C; Hu Q; Song T; Yang R
    BMC Microbiol; 2022 Feb; 22(1):42. PubMed ID: 35114938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
    Ismail A; Shurrab FM; Al-Jighefee HT; Al-Sadeq DW; Qotba H; Al-Shaar IA; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Front Biosci (Landmark Ed); 2021 Jul; 26(7):198-206. PubMed ID: 34340267
    [No Abstract]   [Full Text] [Related]  

  • 19. A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.
    Han X; Wang Y; Li S; Hu C; Li T; Gu C; Wang K; Shen M; Wang J; Hu J; Wu R; Mu S; Gong F; Chen Q; Gao F; Huang J; Long Y; Luo F; Song S; Long S; Hao Y; Li L; Wu Y; Xu W; Cai X; Gao Q; Zhang G; He C; Deng K; Du L; Nai Y; Wang W; Xie Y; Qu D; Huang A; Tang N; Jin A
    Front Immunol; 2021; 12():653189. PubMed ID: 33828563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.